Study design

prospective

Study time

2010-2018

Country

Israel

Object

patients who underwent RALP for cT3 cases

Inclusion criteria

Patients who had received HT, neo-adjuvant chemotherapy, or RT prior to surgery were excluded from the study. Patients who had enhancing lymph nodes on PET/CT or distant metasta_x005fses elsewhere were also excluded from the study

Sample size

79

Topic classification

Focus on RARP

Keypoint

RALP is an oncologic effective procedure for cT3 prostate cancer. Adjuvant/salvage treatment is needed to achieve optimal disease-control.

Year